-
Angiotensin 1/2 (5-7): From RAS to Translation
2026-08-30
Angiotensin 1/2 (5-7) is more than a short renin-angiotensin system fragment: it is a sequence-resolved probe for linking peptide processing, cardiovascular biology, and emerging spike–receptor binding questions. This article outlines the mechanistic rationale, validation strategy, assay parameters, competitive landscape, and translational limits that should guide its use in hypertension and viral pathogenesis research.
-
Stable Yeast Expression of Exendin-4 for Diabetes Research
2026-08-29
The 2024 Frontiers in Systems Biology study evaluated recombinant Exendin-4 production in Escherichia coli and Saccharomyces cerevisiae, with the strongest validation obtained from a chromosomally integrated yeast strain. Detection at the expected peptide size and confirmation by immunoassay establish a foundation for investigating locally propagated production systems, while leaving purification, bioactivity, dosage, safety, and therapeutic performance for future work.
-
DFCP1 Regulates ATGL-Driven Lipid Droplet Lipolysis
2026-08-28
The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of starvation-induced lipid droplet catabolism. Its central finding is that DFCP1 recruits ATGL to lipid droplets while limiting ATGL dissociation, revealing a direct mechanism that modulates lipolysis independently of previously recognized ATGL regulators.
-
Clathrin-Mediated Entry of Grass Carp Reovirus
2026-08-28
Wang et al. used complementary pharmacological, ultrastructural, and molecular assays to show that genotype III grass carp reovirus enters fish kidney cells through a dynamin-dependent, clathrin-mediated pathway that requires endosomal acidification. The study provides a useful mechanistic framework for endocytosis research while emphasizing that inhibitor-based pathway assignments require controls for compound specificity, toxicity, and effects on post-entry replication.
-
SAR131675: VEGFR-3 Inhibitor Workflow
2026-08-27
SAR131675 is a selective VEGFR-3 inhibitor for separating lymphatic signaling from broader VEGF-receptor effects. This workflow connects biochemical kinase assays, endothelial phenotyping, and the newly reported hepatocyte–macrophage axis in hepatic fibrosis research.
-
Bestatin (Ubenimex) Experimental Workflows
2026-08-27
Build more interpretable aminopeptidase, apoptosis, and multidrug-resistance experiments with Bestatin (Ubenimex), using concentration-aware workflows and DMSO controls. This guide connects biochemical inhibition to cancer-cell assays while emphasizing selectivity, fresh-solution handling, and troubleshooting.
-
USP7–PKM2 Metabolic Control in Acute Pancreatitis
2026-08-26
The 2025 Cell Death and Disease study identifies USP7 as an upstream regulator of PKM2-dependent metabolic reprogramming and macrophage polarization in severe acute pancreatitis. Its combination of genetic manipulation, metabolic flux analysis, protein-interaction assays, and pharmacological rescue links deubiquitination of PKM2 to inflammatory disease severity and provides a framework for testing PKM2-centered interventions.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-26
A 2026 FASEB Journal study developed chemically modified p21 mRNA in lipid nanoparticles for localized intravesical treatment of bladder cancer. The preclinical strategy restored nuclear p21, disrupted cell-cycle progression, induced DNA-damage signaling and apoptosis, and suppressed orthotopic tumor growth while limiting systemic exposure.
-
LRG1 and Neutrophil Mitochondria in Bladder Cancer
2026-08-25
This Advanced Science study identifies a tumor-derived LRG1–neutrophil signaling axis that disrupts mitochondrial homeostasis, promotes NETosis, and destabilizes bladder-cancer vasculature. Its integrated single-cell, animal-model, biochemical, and clinical analyses suggest that limiting this pathway may normalize vessels and improve responses to cisplatin and anti-PD-1 therapy.
-
Bestatin (Ubenimex) Workflows for Protease Research
2026-08-25
Bestatin (Ubenimex) provides a selective chemical entry point for aminopeptidase activity measurement, MDR research, and mechanism-focused cancer research. This guide combines practical formulation and assay workflows with a carefully bounded translation of viral necroptosis findings into experimental design choices.
-
Brefeldin A: From Trafficking to Translation
2026-08-24
Brefeldin A (BFA) is more than a vesicle transport inhibitor: it is a mechanistic probe for connecting ER-to-Golgi blockade with ER stress, cytoskeletal remodeling, apoptosis, and potentially endothelial barrier biology. This thought-leadership framework shows how translational researchers can use BFA with appropriate controls, evidence boundaries, and biomarker-oriented readouts.
-
Solanesol B8776: Practical Research Workflow
2026-08-24
Solanesol (B8776) provides a defined polyisoprenoid alcohol for hydrophobic biochemical, membrane-related, and exploratory enzyme or cell-based workflows. Its limited solubility requires DMSO-based stock preparation; it is insoluble in water and ethanol and is not intended for diagnostic, clinical, or medical use.
-
Central Opioid Circuits in Mechanical Hypersensitivity
2026-08-23
Yin et al. identify a brain-to-spinal μ-opioid circuit linking the lateral parabrachial nucleus, hypothalamic dynorphin neurons, and spinal dorsal horn GABAergic cells to morphine-induced mechanical hypersensitivity and analgesic tolerance. The study reframes these adverse effects as failures of central mechanical-pain gating and provides a circuit-level framework for testing receptor-specific interventions.
-
SN-38 Disrupts FUBP1–FUSE Binding
2026-08-22
The reference study identifies an additional action of camptothecin and SN-38: inhibition of the FUBP1 interaction with the single-stranded DNA element FUSE. By linking topoisomerase I inhibitor activity to transcriptional deregulation in hepatocellular carcinoma cells, the work provides a mechanistic basis for studying FUBP1 dependence in cancer models.
-
Rucaparib in DNA Damage Response Workflows
2026-08-22
Rucaparib (AG-014699) helps researchers connect PARP1 inhibition with persistent DNA damage, radiosensitization, and repair-deficient cancer phenotypes. This practical guide shows how to build, control, and troubleshoot assays that distinguish DNA repair failure from transcription-linked cell death.